Navigation Links
Stemina Biomarker Discovery Prepares to Commercialize Autism Diagnostic Products; Appoints New Board Member, Heiner Dreismann, Former Head of Roche Molecular Diagnostics
Date:8/24/2017

Stemina Biomarker Discovery Inc. today announced that Heiner Dreismann, PhD, former head of Roche Molecular Diagnostics, has joined the board of directors to bring his extensive experience in commercialization strategy to the company as it prepares to go to market in early 2018 with its autism diagnostic test panel. Stemina, through its neurological disorders division, NeuroPointDX, is transforming diagnosis and more precise treatment of neurological disorders using its proprietary metabolomics platform technology to diagnose disorders based on the patient’s metabolism. The company’s proprietary technology is already being implemented in the largest clinical study ever conducted of the metabolism of children with autism spectrum disorder (ASD), the Children’s Autism Metabolome Project (CAMP).

Dr. Dreismann, former President and CEO of Roche Molecular Systems and Global Head of Business Development for Roche Diagnostics, led the strategic vision process and established a new strategic architecture for Roche Diagnostics. “We are so pleased that Dr. Dreismann has agreed to join our board to advise us on commercialization strategy for our diagnostic products,” said Stemina’s CEO, Elizabeth Donley. “NeuroPointDX will revolutionize the way autism and other neurological disorders are diagnosed and treated by measuring differences in metabolism of children with ASD across the spectrum.”

“I am excited to join the Stemina Board of Directors as the company has developed and is poised to commercialize a first-in-class, unique product for diagnosis of ASD in children as young as 18 months,” said Dreismann. “Neurological disorders are notoriously difficult to diagnose and treat. NeuroPointDX will greatly improve the precision of diagnosing these disorders.”

“Neurological disorders like autism and schizophrenia, which have historically been defined based on behavioral findings, are now recognized to be comprised of a variety of metabolic and genetic subtypes. Using our proprietary technology, we have identified a series of subtypes of ASD and other neuro-developmental disorders. We have validated a number of these through the CAMP study,” Donley said. “We expect that our approach will provide important information for diagnosis and more precise treatment as well as opportunities to collaborate with drug developers on targeted therapies and clinical trials.”

The CAMP study has enrolled more than 900 patients to date. Enrollment of children ages 18 to 48 months comprised of three groups of children: those with ASD, others with developmental delay but not ASD, and typically-developing children, continues at eight sites across the country. Visit https://neuropointdx.com/camp/ for more information. The CAMP study has validated a panel of metabolic subtypes previously identified in pilot studies of banked blood samples at the MIND Institute at UC-Davis and the Arkansas Children’s Hospital Research Institute.

STEMINA BIOMARKER DISCOVERY:
Stemina Biomarker Discovery was founded in 2007 and is located in Madison, Wisconsin. Stemina delivers the only human cell based test for screening drugs and chemical compounds for their potential to cause birth defects if a woman is exposed during pregnancy.

Visit Stemina at http://www.stemina.com/.

ABOUT NEUROPOINTDX:
NeuroPointDX is a division of Stemina Biomarker Discovery. NeuroPointDX uses its metabolomics platform and proprietary biomarker database to diagnose, treat and develop new therapies for neurological disorders.

Visit NeuroPointDX at http://neuropointdx.com/.

Read the full story at http://www.prweb.com/releases/2017/08/prweb14614855.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. KCAS Bioanalytical and Biomarker Services Welcomes Director of Large Molecule and Biomarker Services
2. Caprion Biosciences Expands Biomarker Panel Portfolio to Include Predictive Tuberculosis (TB) Infections
3. DiaSorin Showcases the Benefits of Utilizing Available Biomarkers to Tailor and Individualize Therapy in Diabetes
4. Biologist Discovers Biomarker That Verifies Commitment in Men
5. Agilent Offers Clinical Research Applications of Accelerated Data Workflows for Biomarker Discovery in Cystic Fibrosis Research
6. Biomarkers in Concussion Management to be Key Topic at Arrowhead Publishers’ 7th Annual Traumatic Brain Injury Conference
7. KCAS Bioanalytical and Biomarker Services Now Offers Ultra-Sensitive Validated Assay for Nicotine Studies
8. BERG Announces BPM 31510 Data Presentations at 2017 AACR in Immuno-Oncology, Glioblastoma Mutiforme, Pancreatic Cancers and Novel Prostate Cancer Biomarker Panel
9. GeneNews Launches Blood-Based, Biomarker Test for Breast Cancer Risk Assessment
10. FDA Grants de novo Clearance for the Brain Sentinel® Monitoring and Alerting System, Bringing a New Biomarker to Help People With Epilepsy
11. Biomarkers Market Worth 53.34 Billion USD by 2021
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2019)... ... 22, 2019 , ... Dr. Douglas Stramel of Advanced Care Veterinary Services ... System (V-PET™) for nearly three years. A proponent of Regenerative Medicine, Dr. ... and began using V-PET™ 2016. V-PET™ is a gravity filtration-based platelet therapy kit ...
(Date:1/20/2019)... ... 2019 , ... Consumers are directing healthcare in many ways, ... changing as many services now exist for patients to order tests without a ... million in 2018, according to Kalorama Information’s new report, The Direct-To-Consumer Testing ...
(Date:1/15/2019)... ... 2019 , ... With the U.S. Congress designating January as Cervical Health Awareness Month , ... announces tips to help reduce the risk of Cervical Cancer. , Cervical cancer ... the #1 most common STD and an STI that almost half of all ...
(Date:1/10/2019)... ... 08, 2019 , ... VGI Medical was founded in 2007 based on an ... to the market including VerteLoc, CerLoc, SiJoin and VerteLP. The VerteLoc and CerLoc systems ... patented dual geometric design to limit motion of the affected spinal segment. Applying the ...
Breaking Biology Technology:
(Date:1/20/2019)... ... ... Boston-based Laboratory as a Service (LaaS) leader, Mass Innovation Labs, has changed ... expansion and service offerings for biotech and life sciences companies. , “Meeting ... more agile and adaptable than ever before. One that doubles-down on the things that ...
(Date:1/10/2019)... ... 2019 , ... When Dr. James L. Sherley, M.D., Ph.D., founder and director ... chapter to the new book Perinatal Stem Cells: Research and Therapy, he knew immediately ... debilitating secret of stem cell medicine. For more than a half-century, stem cell ...
(Date:1/8/2019)... ... January 07, 2019 , ... Sonion , ... hearing instruments and specialty earphones, and Valencell , the leading innovator in ... in canal with an embedded biometric sensor. The BiometRIC measures key vital signs ...
Breaking Biology News(10 mins):